Foreign Regulation
Total 63 Posts
SEC Identifies Baidu and Four More Firms for Delisting
On March 30, the U.S. Securities and Exchange Commission added three more Chinese tech companies and two other companies to its provisional list of companies that fail to comply with U.S. auditing requirements. Talks on the issue between the two governments are still ongoing, with the future of
SEC Adds One Chinese Company for Delisting
The U.S. Securities and Exchange Commission (SEC) added one Chinese company to the provisional list of companies that fail to comply with U.S. auditing requirements.
U.S. Public Hearing Announced on Measures To Prevent Imports from China Made with Forced Labor
The Department of Homeland Security (DHS) and the Forced Labor Enforcement Task Force (FLETF) continue to carry out the regulatory procedures necessary to implement the Uyghur Forced Labor Prevention Act (UFLPA) enacted last year.
FCC Revokes Telecom Services Authority for Two Chinese Companies
Yesterday, the U.S. Federal Communications Commission (FCC) revoked the authority that had previously been granted to two Chinese telecoms companies to operate certain telecom services in the United States.
SEC Identifies Five Chinese Companies for Delisting; Beijing Says "Positive Progress" Is Being Made
The U.S. Securities and Exchange Commission (SEC) identified five Chinese companies as part of the process of delisting Chinese companies that fail to comply with a 2020 U.S. law. In the meantime, Chinese regulators seem confident that "cooperation arrangements" are possible.
Public Comments Filed on DHS Request for Guidance on Preventing Importation of Goods Made With Forced Labor in China
As we reported here, on January 24 the U.S. Department of Homeland Security, on behalf of the Forced Labor Enforcement Task Force (FLETF), sought input from the public on "how best to ensure that goods, wares, articles, and merchandise mined, produced, or manufactured wholly or in part with
FDA Advisers Request More Data for Drug Trialed in China, Citing Lack of Diversity and Different Standards
Recently, an advisory committee of the U.S. Food and Drug Administration voted in favor of requiring additional trial data in order for a China-trialed medicine to obtain FDA approval. This decision could have major implications for future regulatory approval applications for medicines developed in China. The FDA's